Welcome to ARUP Pain Management

ARUP’s unique approach to pain management patient monitoring offers physicians multiple choices.

In select situations, a quantitative result can assist physicians in the monitoring or treatment of their patients. As a complement to our qualitative mass spectrometry panels, ARUP offers physicians an immunoassay with auto reflex to LC/MS/MS quantitative results.

The extended pain management panel was designed to meet the granularity requirements of monitoring pain management patients while being mindful of the cost to both the patient and the health system.

If a confirmation is needed, ARUP will automatically reflex to LC/MS/MS metholology on any of the drug classes. Our three panels complement pain management testing requirements while helping reduce patient out-of-pocket expenses.

Resolving Unanswered Questions

Immunoassay screens and point-of-care cups may report opiates as a class but not as individual drugs, leaving certain questions unanswered: What was positive? What was tested? Benzodiazepines, for example, tend to be a source of false negatives, as they are poorly sensitive to the metabolite of clonazepam. ARUP’s qualitative mass spectrometry panels use advanced technologies, reducing unexpected or ambiguous results and the need for costly confirmation testing.